Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its upcoming presentations at the 75th American Academy of Neurology (AAN) Annual Meeting occurring in Boston from April 22-27, 2023. Key highlights include an oral presentation on April 27, focusing on the AOC 1001 Phase 1/2 MARINA™ trial, which evaluates the safety, biomarker, and functional data for patients with Myotonic Dystrophy Type 1 (DM1). Additionally, a poster presentation on April 23 will cover the AOC 1020 trial design for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Avidity's commitment is to advance its RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), targeting diseases previously considered untreatable. For more information, visit Avidity's website.
- None.
- None.
SAN DIEGO, April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced presentations at the 75th American Academy of Neurology (AAN) Annual Meeting, including an oral presentation on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2 MARINA™ trial. The 75th AAN Annual Meeting is taking place in Boston, Mass., April 22-27, 2023.
ORAL PRESENTATION
April 27, 2023: 3:42 p.m. - 3:54 p.m. ET
- Preliminary Assessment of the Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA)
POSTER PRESENTATION
April 23, 2023: 5:30 p.m. - 6:30 p.m. ET
- Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE) Trial Design
Once available, both the presentation and poster will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Investor Contact:
Kathleen Gallagher
(858) 401-7900 x550
investors@aviditybio.com
Media Contact:
Navjot Rai
(858) 401-7900 x550
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-the-75th-american-academy-of-neurology-annual-meeting-301798401.html
SOURCE Avidity Biosciences, Inc.
FAQ
What will Avidity Biosciences present at the AAN Annual Meeting?
When is Avidity Biosciences' oral presentation at the AAN Annual Meeting?
What diseases are AOC 1001 and AOC 1020 targeting?
Where is the 75th AAN Annual Meeting being held?
What is the ticker symbol for Avidity Biosciences?
